The rise of the large-volume purchaser of health care scared the industry's strategists into hyperactivity, prompting moves-most prominently by Merck, SmithKline and Lilly-into the service business. These services were designed to take pricing pressure off the companies' core businesses by putting the cost of products into a larger context and helping customers save money in other areas; in the process perhaps also creating another revenue stream for the manufacturer.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.